GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (HKSE:01099) » Definitions » PB Ratio

Sinopharm Group Co (HKSE:01099) PB Ratio : 0.83 (As of Dec. 12, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-12), Sinopharm Group Co's share price is HK$21.55. Sinopharm Group Co's Book Value per Share for the quarter that ended in Jun. 2024 was HK$26.06. Hence, Sinopharm Group Co's PB Ratio of today is 0.83.

The historical rank and industry rank for Sinopharm Group Co's PB Ratio or its related term are showing as below:

HKSE:01099' s PB Ratio Range Over the Past 10 Years
Min: 0.6   Med: 1.59   Max: 3.21
Current: 0.83

During the past 13 years, Sinopharm Group Co's highest PB Ratio was 3.21. The lowest was 0.60. And the median was 1.59.

HKSE:01099's PB Ratio is ranked better than
74.26% of 101 companies
in the Medical Distribution industry
Industry Median: 1.24 vs HKSE:01099: 0.83

During the past 12 months, Sinopharm Group Co's average Book Value Per Share Growth Rate was 6.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 6.90% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 10.30% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 9.60% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sinopharm Group Co was 77.30% per year. The lowest was 5.90% per year. And the median was 13.50% per year.

Back to Basics: PB Ratio


Sinopharm Group Co PB Ratio Historical Data

The historical data trend for Sinopharm Group Co's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co PB Ratio Chart

Sinopharm Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.60 0.88 0.70 0.81 0.78

Sinopharm Group Co Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.81 1.00 0.78 0.80

Competitive Comparison of Sinopharm Group Co's PB Ratio

For the Medical Distribution subindustry, Sinopharm Group Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinopharm Group Co's PB Ratio Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's PB Ratio distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's PB Ratio falls into.



Sinopharm Group Co PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Sinopharm Group Co's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2024)
=21.55/26.06
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Sinopharm Group Co  (HKSE:01099) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Sinopharm Group Co PB Ratio Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinopharm Group Co Business Description

Traded in Other Exchanges
Address
No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2023. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
Executives
Blackrock, Inc. 2201 Interest of corporation controlled by you
Lazard Asset Management Llc 2102 Investment manager
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Citigroup Inc. 2502 Approved lending agent
Fmr Llc 2201 Interest of corporation controlled by you

Sinopharm Group Co Headlines

No Headlines